Advanced search
Showing result 1 - 5 of 12 swedish dissertations matching the above criteria.
-
1. Molecular biology of Brouton's tyrosine kinase
Abstract : X-linked agammaglobulinemia (XLA) is caused by an arrest in the B lymphocyte differentiation. XLA patients lack mature B-cells and subsequently antibody production. The defective gene causing XLA is the BTK gene, which codes for the protein Bruton s tyrosine kinase (Btk), a cytoplasmic enzyme related to the Src family of kinases. READ MORE
-
2. Chemical and physical incorporation of bio-molecules into wood materials for energy storage
Abstract : The environmental impact of fossil-based materials in the building industry and significant energy consumption in residential buildings have urged new research areas in using bio-based, renewable and sustainable materials for production of energy smart bio-based envelopes for building applications. This can be achieved by incorporation of bio-based phase change materials (BPCMs) in wood materials for energy storage in residential buildings. READ MORE
-
3. Molecular dissection of B-lymphocyte signalling using expression profiling
Abstract : Gene expression profiling and bioinformatics have emerged into playing a large and diverse role in many aspects of both the clinical and molecular research. These two approaches have in this thesis work been used in combination in order to shed light to the role of Bruton's tyrosine kinase (Btk) in B-lymphocyte development and signal transduction. READ MORE
-
4. Subcellular localization and signalling of Brutons tyrosine kinase (Btk)
Abstract : Brutons tyrosine kinase (Btk) is a non-receptor tyrosine kinase related to the Src family of kinases. Mutations in various parts of the gene have been shown to cause X-linked agammaglobulinemia (XLA), a primary immunodeficiency in humans, characterized by a defect in B-cell development. READ MORE
-
5. Bruton tyrosine kinase in immunodeficiency and in B-cell malignancy
Abstract : BTK inhibitors have induced high response rates in the treatment of leukemias and lymphomas. Ibrutinib is the first-in-class US Food and Drug Administration (FDA)-approved BTK covalent inhibitor to treat chronic lymphocytic leukemia (CLL). However, a sub-group of patients develops resistance to ibrutinib therapy. READ MORE